Skip to main content

Table 3 Significant Toxicities results

From: Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials

Toxicity Pts (RCTs) RR (95% CI) p-value Het. (p) AD (%) NNH
Hypertension 3,841 (5) 5.15 (1.60, 16.6) 0.006 < 0.0001 4.5 22
Proteinuria 3,841 (5) 9.55 (3.44, 26.5) < 0.0001 0.96 0.4 250
Neurotoxicity 3,379 (4) 1.20 (1.01, 1.43) 0.044 0.61 2.6 39
Febrile Neutropenia 3,379 (4) 1.39 (1.07, 1.83) 0.015 0.60 2.1 46
Bleeding 3,841 (5) 3.05 (1.13, 8.23) 0.028 0.56 0.6 175
  1. Pts: patients; RCTs: randomized clinical trials; HR: hazard ratio; CI: confidence intervals; Het.: heterogeneity; p: p-value; AD: absolute difference; NNH: number needed to harm.